The BEAVER trial, a phase II study, is evaluating the combination of encorafenib (a BRAF inhibitor) and binimetinib (a MEK inhibitor) in advanced solid tumors, including CRC with non-V600 BRAF mutations [41]. The gene discussed is BRAF; the disease is colorectal carcinoma.